Search research articles
Contact Us
Filters
Showing results (11-20 of 79) with videos related to
Page
of 8
Sort By:
Annals of Translational Medicine
|
October 22, 2015
Recent advances in the treatment of melanoma with BRAF and MEK inhibitors
Eva Muñoz-Couselo, Jesús Soberino García, José Manuel Pérez-García, et al.
Clinical Pharmacology in Drug Development
|
May 1, 2021
Evaluation of the Effects of Repeat-Dose Dabrafenib on the Single-Dose Pharmacokinetics of Rosuvastatin (OATP1B1/1B3 Substrate) and Midazolam (CYP3A4 Substrate)
Noelia Nebot, Christina S Won, Victor Moreno, et al.
Nature Reviews. Clinical Oncology
|
December 15, 2010
HER2 and hormone receptor-positive breast cancer--blocking the right target
Javier Cortés, Cristina Saura, Meritxell Bellet, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
April 29, 2022
Retreatment With Immune Checkpoint Inhibitors After a Severe Immune-Related Hepatitis: Results From a Prospective Multicenter Study
Mar Riveiro-Barciela, Ana Barreira-Díaz, Ana Callejo-Pérez, et al.
Oncogene
|
March 8, 2025
Transcriptional reprogramming triggered by neonatal UV radiation or Lkb1 loss prevents BRAF<sup>V600E</sup>-induced growth arrest in melanocytes
Kimberley McGrail, Paula Granado-Martínez, Roberto Orsenigo, et al.
Nature
|
October 10, 2018
A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy
Adriana Sánchez-Danés, Jean-Christophe Larsimont, Mélanie Liagre, et al.
Cancers
|
January 11, 2024
Mucosal Melanoma Clinical Management and Prognostic Implications: A Retrospective Cohort Study
Laia Clavero-Rovira, Álvaro Gómez-Tomás, Patricia Bassas-Freixas, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
April 25, 2020
Immune-related hepatitis related to checkpoint inhibitors: Clinical and prognostic factors
Mar Riveiro-Barciela, Ana Barreira-Díaz, Judit Vidal-González, et al.
Oncotargets and Therapy
|
December 6, 2021
Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice
Mª Del Carmen Álamo, Sebastian Ochenduszko, Guillermo Crespo, et al.
Molecular Oncology
|
August 8, 2024
Loss of Lkb1 cooperates with Braf<sup>V600E</sup> and ultraviolet radiation, increasing melanoma multiplicity and neural-like dedifferentiation
Kimberley McGrail, Elena González-Sánchez, Paula Granado-Martínez, et al.
Page
of 8
Search research articles
Search
Showing results (11-20 of 79) with videos related to
Sort By:
Page
of 8
Annals of Translational Medicine
|
October 22, 2015
Recent advances in the treatment of melanoma with BRAF and MEK inhibitors
Eva Muñoz-Couselo, Jesús Soberino García, José Manuel Pérez-García, et al.
Clinical Pharmacology in Drug Development
|
May 1, 2021
Evaluation of the Effects of Repeat-Dose Dabrafenib on the Single-Dose Pharmacokinetics of Rosuvastatin (OATP1B1/1B3 Substrate) and Midazolam (CYP3A4 Substrate)
Noelia Nebot, Christina S Won, Victor Moreno, et al.
Nature Reviews. Clinical Oncology
|
December 15, 2010
HER2 and hormone receptor-positive breast cancer--blocking the right target
Javier Cortés, Cristina Saura, Meritxell Bellet, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
April 29, 2022
Retreatment With Immune Checkpoint Inhibitors After a Severe Immune-Related Hepatitis: Results From a Prospective Multicenter Study
Mar Riveiro-Barciela, Ana Barreira-Díaz, Ana Callejo-Pérez, et al.
Oncogene
|
March 8, 2025
Transcriptional reprogramming triggered by neonatal UV radiation or Lkb1 loss prevents BRAF<sup>V600E</sup>-induced growth arrest in melanocytes
Kimberley McGrail, Paula Granado-Martínez, Roberto Orsenigo, et al.
Nature
|
October 10, 2018
A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy
Adriana Sánchez-Danés, Jean-Christophe Larsimont, Mélanie Liagre, et al.
Cancers
|
January 11, 2024
Mucosal Melanoma Clinical Management and Prognostic Implications: A Retrospective Cohort Study
Laia Clavero-Rovira, Álvaro Gómez-Tomás, Patricia Bassas-Freixas, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
April 25, 2020
Immune-related hepatitis related to checkpoint inhibitors: Clinical and prognostic factors
Mar Riveiro-Barciela, Ana Barreira-Díaz, Judit Vidal-González, et al.
Oncotargets and Therapy
|
December 6, 2021
Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice
Mª Del Carmen Álamo, Sebastian Ochenduszko, Guillermo Crespo, et al.
Molecular Oncology
|
August 8, 2024
Loss of Lkb1 cooperates with Braf<sup>V600E</sup> and ultraviolet radiation, increasing melanoma multiplicity and neural-like dedifferentiation
Kimberley McGrail, Elena González-Sánchez, Paula Granado-Martínez, et al.
Page
of 8